Compare DexCom, Inc. (DXCM) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? DexCom, Inc. trades at $77.79 (market cap $28.06B), while GraniteShares 2x Long NVDA Daily ETF trades at $31.44. The key difference: DexCom, Inc. is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | NVDL | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $43.02 |
52-Week Low | $54.84 | $21.76 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $31.635, down 4.63% on the day, reflecting the volatility inherent in leveraged ETFs. The technical picture shows a bullish bias in moving averages but neutral oscillators, with key support at $30 and resistance at $34. Recent corporate actions include two 1:3 stock splits in late June 2026, adjusting share structure.
The outlook for NVDL is heavily tied to NVIDIA's performance, offering amplified daily returns but significant risk from volatility decay. Investment opportunity exists for traders bullish on NVIDIA's AI dominance, but risks include leveraged ETF structural decay and dependence on a single stock's momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
